Table 2.

Relationship between baseline C-peptide levels and follow-up measurements of glucose control

	Model 1	Model 2	Model 3
Severe hypoglycemia†	0.68 (0.60, 0.77)*	0.70 (0.61, 0.80)*	0.77 (0.66, 0.88)*
Mean Glucose CV (1 SD)‡	− 0.12 (− 0.14, − 0.10)*	− 0.10 (− 0.12, − 0.08)*	− 0.07 (− 0.10, − 0.05)*
Mean Glucose ARV (1 SD)‡	− 0.12 (− 0.15, − 0.10)*	− 0.10 (− 0.13, − 0.08)*	− 0.08 (− 0.10, − 0.05)*

Outcomes were any occurrence of severe hypoglycemia, mean updated glucose coefficient of variation (CV) or average real variability (ARV). Model 1, adjusted for glucose-lowering group; Model 2, additionally adjusted for baseline age, race/ethnicity, diabetes duration, HbA_1c, body mass index and eGFR; Model 3, additionally adjusted for insulin and sulphonylureas use. Data are Odds ratios (OR) or standardized β-estimates (95% CI) per 1 SD of C-peptide levels

^†Logistic regression, ^‡Mixed model linear regression with random intercept, *p < 0.05